These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2965374)

  • 1. [Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies].
    Philip-Joet F; Bruguerolle B; Parrel M; Vestri R; Arnaud A
    Presse Med; 1988 Feb; 17(5):193-6. PubMed ID: 2965374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unequal twice-daily, sustained-release theophylline dosing in chronic obstructive pulmonary disease.
    Bruguerolle B; Philip-Joet F; Parrel M; Arnaud A
    Chronobiol Int; 1987; 4(3):381-5. PubMed ID: 3315267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction.
    Rivington RN; Calcutt L; Hodder RV; Stewart JH; Aitken TL
    Am J Med; 1988 Jul; 85(1B):48-53. PubMed ID: 3041826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescription of Theostat 300 as a single evening dose].
    Germouty J; Bida C; Moreau L
    Rev Pneumol Clin; 1987; 43(5):262-5. PubMed ID: 3324266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of controlled-release theophylline in chronic airways obstruction.
    Dal Negro R; Turco P; Pomari C; Cordaro CI
    J Int Med Res; 1987; 15(6):391-6. PubMed ID: 3436486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dosing time on the pharmacokinetics and pharmacodynamics of a 'once-a-day' sustained release theophylline preparation.
    Lamont H; Pauwels R; Van der Straeten M
    Br J Clin Pharmacol; 1987 Dec; 24(6):735-42. PubMed ID: 3440095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic obstructive pulmonary disease with two sustained-release theophylline preparations.
    Giosue S; Bernocchi D; Parola D; Munno R; Mancini P
    J Int Med Res; 1987; 15(6):352-60. PubMed ID: 3325318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.
    Taylor DR; Duffin D; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1984 Jul; 18(1):27-30. PubMed ID: 6743488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.
    Murciano D; Auclair MH; Pariente R; Aubier M
    N Engl J Med; 1989 Jun; 320(23):1521-5. PubMed ID: 2498658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1982 Apr; 13(4):569-71. PubMed ID: 7066172
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
    Cova D; Cuglituri G; Rossini L; Bonfardeci G
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):273-5. PubMed ID: 2737795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
    Riddington CJ; Shipman AJ
    Br J Clin Pract; 1985 Apr; 39(4):148-53. PubMed ID: 3893504
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
    Arens PJ
    Med Klin Prax; 1982 Aug; 77(18):48-53, 67. PubMed ID: 6752679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical functional study of a new delayed-action preparation of "once a day" anhydrous theophylline in patients with chronic obstructive bronchopneumopathy].
    Gatto PG; Bruzzoni A; Valenti V
    Clin Ter; 1989 Jul; 130(1):45-9. PubMed ID: 2529079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with sustained-release theophylline.
    Myhre KI; Arnulf V; Walstad RA
    Pharmatherapeutica; 1985; 4(2):92-7. PubMed ID: 3903782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of plasma levels of 2 delayed-action theophyllines: Theostat 200 and Theodur 200, after a single evening dose].
    Philip-Joet F; Bruguerolle B; Lagier F; Arnaud A
    Rev Pneumol Clin; 1986; 42(6):279-83. PubMed ID: 3563255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of a new delayed-release anhydrous theophylline by single daily administration in the treatment of reversible bronchial obstruction. Comparison with a delayed-release preparation administered twice daily].
    Baronti A; Verdiani P; Di Carlo S
    Clin Ter; 1987 Sep; 122(6):437-40. PubMed ID: 2972456
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of withdrawal of sustained-release theophylline in patients with chronic obstructive lung disease.
    Aamodt T; Dahle R; Horgen O
    Allergy; 1988 Aug; 43(6):411-4. PubMed ID: 3189721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The comparative efficacy of the prolonged-action theophylline preparations Theopek and Euphylong in elderly patients with chronic obstructive lung diseases].
    Salikova VV; Nonikov VE; Belousov IuB
    Ter Arkh; 1993; 65(8):41-4. PubMed ID: 8211801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.